Immunological mechanisms of inducing HIV immunity in infants.
Broadly neutralizing antibodies
Early life
HIV
Immune system
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
16 01 2020
16 01 2020
Historique:
received:
08
08
2019
revised:
01
11
2019
accepted:
05
11
2019
pubmed:
26
11
2019
medline:
13
2
2021
entrez:
26
11
2019
Statut:
ppublish
Résumé
The potential advantages and unique challenges of the early life immune system for the development of HIV-specific broadly neutralizing antibodies were discussed during a workshop entitled "Immunological Mechanisms of Inducing HIV Immunity in Infants" sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in conjunction with the 2018 HIVR4P Conference held in Madrid, Spain. A safe and effective HIV vaccine remains a critical need in the fight against the HIV pandemic, especially to prevent emerging infections in infants, adolescents, and young adults. To successfully target these populations, a vaccine should ideally induce protective immune responses during childhood. Interestingly, several recent studies highlighting differences in immune responses between adults and children have suggested that the early life immune system could present advantages for the elicitation of broadly neutralizing antibodies (bnAbs), a response highly desired for an HIV vaccine. Notably, HIV-infected children develop bnAbs responses earlier and more frequently than infected adults; with emerging evidence that the pathways of elicitation of bnAb lineages may differ between adults and children. Moreover, there is precedent for the prevention of lifelong infections with pediatric immunization, and early life provides a unique window of opportunity for the administration of a multi-dose HIV vaccine that will likely be needed to achieve protective immunity. Further understanding of how the distinct early life immune system can be harnessed to trigger bnAb lineages for induction of durable and polyfunctional HIV-specific immunity is warranted. This strategy will include testing promising HIV vaccine candidates in pediatric populations in preclinical and clinical studies. Novel approaches to identify molecular markers of protection are also key to guide and accelerate pediatric HIV vaccine development.
Identifiants
pubmed: 31761501
pii: S0264-410X(19)31518-X
doi: 10.1016/j.vaccine.2019.11.011
pmc: PMC6955149
mid: NIHMS1065106
pii:
doi:
Substances chimiques
AIDS Vaccines
0
Antibodies, Neutralizing
0
HIV Antibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-415Subventions
Organisme : NIAID NIH HHS
ID : U19 AI118608
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI117915
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131978
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143370
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201800047C
Pays : United States
Informations de copyright
Copyright © 2019.
Références
Nature. 2017 Aug 3;548(7665):108-111
pubmed: 28726771
Semin Immunopathol. 2017 Nov;39(6):605-613
pubmed: 28971246
J Virol. 2012 Sep;86(18):9566-82
pubmed: 22740394
J Infect Dis. 2007 Oct 15;196(8):1153-62
pubmed: 17955433
PLoS Pathog. 2016 Aug 25;12(8):e1005815
pubmed: 27560183
Clin Infect Dis. 2019 Mar 19;68(7):1193-1203
pubmed: 30215689
Vaccine. 2004 Jan 2;22(3-4):511-9
pubmed: 14670334
Cell. 2018 Aug 23;174(5):1277-1292.e14
pubmed: 30142345
PLoS Pathog. 2010 Aug 05;6(8):e1001028
pubmed: 20700449
Nat Med. 2014 Jun;20(6):655-8
pubmed: 24859529
Front Immunol. 2018 Oct 26;9:2441
pubmed: 30416503
Cell Rep. 2017 Dec 26;21(13):3681-3690
pubmed: 29281818
J Virol. 2018 Aug 16;92(17):
pubmed: 29950423
Nat Commun. 2019 May 16;10(1):2190
pubmed: 31097697
Immunity. 2017 Mar 21;46(3):350-363
pubmed: 28329702
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
Cell Rep. 2016 Nov 1;17(6):1560-1570
pubmed: 27806295
J Virol. 2019 Jul 17;93(15):
pubmed: 31092583
J Virol. 2018 Sep 26;92(20):
pubmed: 30089691
Allergol Int. 2017 Oct;66(4):515-522
pubmed: 28826938
Sci Transl Med. 2016 Sep 28;8(358):358ra125
pubmed: 27683550
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Immunol Rev. 2017 Jan;275(1):145-160
pubmed: 28133802
J Infect Dis. 2015 Feb 15;211(4):508-17
pubmed: 25170104
Nat Commun. 2017 Nov 23;8(1):1732
pubmed: 29170366
Nat Med. 2010 Oct;16(10):1117-9
pubmed: 20890292
J Virol. 2019 Feb 5;93(4):
pubmed: 30429339
Nat Commun. 2019 Mar 12;10(1):1092
pubmed: 30862783
Cell Host Microbe. 2018 Jun 13;23(6):759-765.e6
pubmed: 29861171
Annu Rev Med. 2016;67:185-200
pubmed: 26565674
Immunol Rev. 2017 Jan;275(1):203-216
pubmed: 28133796
JCI Insight. 2017 Mar 23;2(6):e91020
pubmed: 28352660
PLoS Pathog. 2018 Apr 19;14(4):e1006944
pubmed: 29672607
J Virol. 2017 Dec 14;92(1):
pubmed: 29021402
Curr Opin Immunol. 2018 Aug;53:143-151
pubmed: 29775847
J Immunol. 2016 Dec 1;197(11):4413-4424
pubmed: 27793997
PLoS One. 2017 Jan 3;12(1):e0169247
pubmed: 28046039
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
J Exp Med. 2017 Aug 7;214(8):2283-2302
pubmed: 28698284
Sci Transl Med. 2019 Feb 27;11(481):
pubmed: 30814336
Cell. 2016 Jun 30;166(1):77-87
pubmed: 27345369
Front Immunol. 2018 Sep 12;9:1975
pubmed: 30258437
Immunol Rev. 2017 Jan;275(1):62-78
pubmed: 28133804